



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Paper No. 15

MAILED

Sprung, Felfe, Horn,
Lynch and Kramer
600 Third Ave.
New York, N.Y. 10016

Applicant	Bodo Junge, et. al	JAN 7 1980
Ser. No.	936,280	PATENT & TRADEMARK OFFICE
Filed	08/23/78	
For New 3,4,5-TRIHYDROXYPIPERIDINE COMPOUNDS, THEIR PRODUCTION AND THEIR MEDICINAL USE		

The case referred to above has been forwarded to the Board of Patent Interferences because it is adjudged to interfere with other cases hereafter specified. Attention is directed to the fact that this interference is declared under the Rules of Practice as amended effective July 1, 1965, and as further amended effective to the date of this notice. The interference is identified as No. 100398

By direction of the Commissioner of Patents and Trademarks and as required by 35 U.S.C. 135(c), notice is hereby given the parties of the requirement of the law for filing in the Patent and Trademark Office a copy of any agreement "in connection with or in contemplation of the termination of the interference."

In view of the accompanying order to show cause entered in this interference under Rule 228 no schedule of times is set. Rule 207(e).

The schedule of times under Rule 207(b) is set as follows:

(1) The preliminary statement (Rules 215 et seq.) must be filed and opposing parties notified of its filing by **MAR 7 1980**

(It should be filed in a sealed envelope bearing the name of the party filing it and the number of the interference.)

(2) A copy of the preliminary statement and attachment's must be served on each opposing party from whom a notice of filing a preliminary statement has been received by **24 MAR 1980**

(3) Motions under Rule 231 must be filed by **FEB 22 1980** *5/19/80*

If you expect to obtain the benefit of any application filed in this or any other country, including any intermediate applications, you must file a motion under Rule 231(e)(4) unless such application is specified in this notice. Rule 224.

The interference involves your application identified above and:

Pertinent information regarding the parties involved in this interference is as follows:

Junior Party

Applicants: Bodo Junge, Hans Peter Krause, Lutz Muller, Walter Puls

Addresses: Bayer AG, Wuppertal-1, Germany 5600, respectively

Serial No.: 936,280 filed 08/23/78

For: NEW 3,4,5-TRIHYDROXYPIPERIDINE COMPOUNDS, THEIR PRODUCTION AND THEIR MEDICINAL USE

Assignee: Bayer Aktiengesellschaft, Leverkusen, Germany

Attorneys of Record: Arnold Sprung, Frank M. Murphy, Peter F. Felfe, Leonard Horn, John E. Lynch, Nathaniel D. Kramer

Address: Sprung, Felfe, Horn, Lynch & Kramer
600 Third Ave., New York, N.Y. 10016

Senior Party

Applicants: Shingo Matsumura, Hiroshi Enomoto, Yoshiaki Aoyagi
Yoshiaki Yoshikuni, Kohei Kura, Masahiro Yagi
Ichiro Shirahase

Addresses: 22-40 Kuburagi Tanabecho Tsuzuki-gun, Kyoto-fu
610-03, Japan, 707 Nagaokakyō Skyheights, 26-3
Babamiba-Hashiri, Nagaokakyō-shi 617, Japan,
19-103 Ōgurusu Kitadanchi, 6 Manami Gotcho, Ōgurusu,
Fushimi-ku, Kyoto 601-13, Japan, 46 Hanazonocho
Karahashi, Minami-Ku, Kyoto 601, Japan, 1876-7
Wakabacho 5-chome, Ōmihachiman-shi, Shiga-523, Japan
5-24 Higashiyagura 3-Chome, Kusatsu-shi, Shiga
525, Japan, c/o Otoyaryo, 39 Sakanotsujicjo, Oyake,
Yamashina-ku, Kyoto 607 Japan.

Serial No.: 033,990 filed 04/27/79

For: N-ALKENYLMORANOLINE DERIVATIVES

Assignee: Nippon Shinyaku Co., Ltd., Kyoto, Japan


Accorded benefit of: Japan Application No. 5351023 filed 04/28/78

Attorneys of Record: Albert L. Jacobs, Mark H. Sparrow, Albert L. Jacobs, Jr., Bruce M. Collins, Jesse D. Reingold

Address: Jacobs and Jacobs
521 Fifth Ave.
New York, N.Y. 10017

Count 1

A compound of the formula:



wherein R is C₂-C₂₀ alkenyl or a pharmaceutically acceptable acid addition salt thereof.

The relation of the counts of the interference to the claims of the respective parties is as follows:

<u>Counts</u>	<u>Junge et. al.</u>	<u>Matsumura et al</u>
1	50(p)	11(p)

After termination of this interference, this application will be subject to further examination under Rule 1.266. Claims 5-10, 18, 24-32, 34-38, 42-43, 47 will be held subject to rejection as unpatentable over the issue in the event of an award of priority adverse to applicant.


Michael J. Ahlers
Patent Interference Examiner